You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
INDICATIONS AS AT 24 March 2004: Doxycycline is primarily bacteriostatic and is thought to exert its antimicrobial effect by the inhibition of protein synthesis. Doxycycline is active against a wide range of gram positive and gram negative organisms. NOTE: THE 50 mg CAPSULE IS NOT A PAEDIATRIC FORMULATION. Doryx is indicated in the treatment of infections caused by the following micro-organisms: Mycoplasma pneumoniae: primary atypical pneumonia. Rickettsiae: Queensland tick typhus, typhus fever and Q fever Agents of psittacosis. Calymmatobacterium (Donovania) granulomitis: granuloma inguinale. Agents of lymphogranuloma venereum. Borreliae: relapsing fever. Chlamydia trachomatis. Doryx is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral Doryx alone, or in combination with topical agents. Doryx is indicated in the treatment of infections caused by the following gram negative micro-organisms: Vibrio species: cholera. Brucella species: brucellosis (in conjunction with streptomycin). Yersinia pestis: plague. Francisella tularensis: tularemia. Bartonella bacilliformis: Bartonellosis. Bacteroides species. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Treponema pallidum: syphilis. Treponema pertenue: yaws. Neisseria gonorrhoea: gonorrhoea (see Dosage and Administration). Doryx is not the drug of choice in the treatment of any type of Staphylococcal infection or infections caused by Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes, Streptococcus faecalis, or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. Doxycycline should not be used in these infections unless the organism has been shown to be sensitive. For upper respiratory tract infections due to group A beta-haemolytic streptococci (including prophylaxis of rheumatic fever) penicillin is the usual drug of choice. Doxycycline is active against both pre-erythroycitic and asexual bloodstages of Plasmodium falciparum. The tetracyclines are only partially active against the pre-erythrocytic stages of Plasmodium vivax and protection depends on drug suppression of the blood stages. Doxycycline has no activity against the relapsing forms (hypnozoites) of Plasmodium vivax. Doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by Plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by Plasmodium vivax. Doxycycline is only able to suppress malaria caused by P. vivax. As there are relatively few locations where P. vivax does not co-exist to some extent with P. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine. In acute intestinal amoebiasis Doryx may be a useful adjunct to amoebicides. In severe acne Doryx may be a useful adjunctive therapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
INDICATIONS AS AT 24 March 2004: Doxycycline is primarily bacteriostatic and is thought to exert its antimicrobial effect by the inhibition of protein synthesis. Doxycycline is active against a wide range of gram positive and gram negative organisms. NOTE: THE 50 mg CAPSULE IS NOT A PAEDIATRIC FORMULATION. Doryx is indicated in the treatment of infections caused by the following micro-organisms: Mycoplasma pneumoniae: primary atypical pneumonia. Rickettsiae: Queensland tick typhus, typhus fever and Q fever Agents of psittacosis. Calymmatobacterium (Donovania) granulomitis: granuloma inguinale. Agents of lymphogranuloma venereum. Borreliae: relapsing fever. Chlamydia trachomatis. Doryx is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral Doryx alone, or in combination with topical agents. Doryx is indicated in the treatment of infections caused by the following gram negative micro-organisms: Vibrio species: cholera. Brucella species: brucellosis (in conjunction with streptomycin). Yersinia pestis: plague. Francisella tularensis: tularemia. Bartonella bacilliformis: Bartonellosis. Bacteroides species. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Treponema pallidum: syphilis. Treponema pertenue: yaws. Neisseria gonorrhoea: gonorrhoea (see Dosage and Administration). Doryx is not the drug of choice in the treatment of any type of Staphylococcal infection or infections caused by Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes, Streptococcus faecalis, or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. Doxycycline should not be used in these infections unless the organism has been shown to be sensitive. For upper respiratory tract infections due to group A beta-haemolytic streptococci (including prophylaxis of rheumatic fever) penicillin is the usual drug of choice. Doxycycline is active against both pre-erythroycitic and asexual bloodstages of Plasmodium falciparum. The tetracyclines are only partially active against the pre-erythrocytic stages of Plasmodium vivax and protection depends on drug suppression of the blood stages. Doxycycline has no activity against the relapsing forms (hypnozoites) of Plasmodium vivax. Doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by Plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by Plasmodium vivax. Doxycycline is only able to suppress malaria caused by P. vivax. As there are relatively few locations where P. vivax does not co-exist to some extent with P. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine. In acute intestinal amoebiasis Doryx may be a useful adjunct to amoebicides. In severe acne Doryx may be a useful adjunctive therapy.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
INDICATIONS AS AT 24 March 2004: Doxycycline is primarily bacteriostatic and is thought to exert its antimicrobial effect by the inhibition of protein synthesis. Doxycycline is active against a wide range of gram positive and gram negative organisms. NOTE: THE 50 mg CAPSULE IS NOT A PAEDIATRIC FORMULATION. Doryx is indicated in the treatment of infections caused by the following micro-organisms: Mycoplasma pneumoniae: primary atypical pneumonia. Rickettsiae: Queensland tick typhus, typhus fever and Q fever Agents of psittacosis. Calymmatobacterium (Donovania) granulomitis: granuloma inguinale. Agents of lymphogranuloma venereum. Borreliae: relapsing fever. Chlamydia trachomatis. Doryx is indicated in the treatment of trachoma, although the infectious agent is not always eliminated, as judged by immunofluorescence. Inclusion conjunctivitis may be treated with oral Doryx alone, or in combination with topical agents. Doryx is indicated in the treatment of infections caused by the following gram negative micro-organisms: Vibrio species: cholera. Brucella species: brucellosis (in conjunction with streptomycin). Yersinia pestis: plague. Francisella tularensis: tularemia. Bartonella bacilliformis: Bartonellosis. Bacteroides species. When penicillin is contraindicated, doxycycline is an alternative drug in the treatment of infections due to: Treponema pallidum: syphilis. Treponema pertenue: yaws. Neisseria gonorrhoea: gonorrhoea (see Dosage and Administration). Doryx is not the drug of choice in the treatment of any type of Staphylococcal infection or infections caused by Streptococcus pneumoniae, Haemophilus influenzae, Streptococcus pyogenes, Streptococcus faecalis, or any type of enteric bacteria because many strains of these organisms have been shown to be resistant to doxycycline. Doxycycline should not be used in these infections unless the organism has been shown to be sensitive. For upper respiratory tract infections due to group A beta-haemolytic streptococci (including prophylaxis of rheumatic fever) penicillin is the usual drug of choice. Doxycycline is active against both pre-erythroycitic and asexual bloodstages of Plasmodium falciparum. The tetracyclines are only partially active against the pre-erythrocytic stages of Plasmodium vivax and protection depends on drug suppression of the blood stages. Doxycycline has no activity against the relapsing forms (hypnozoites) of Plasmodium vivax. Doxycycline is indicated, in adults and children older than 10 years, as chemoprophylaxis for malaria caused by Plasmodium falciparum and, in combination with other antimalarial agents, against malaria caused by Plasmodium vivax. Doxycycline is only able to suppress malaria caused by P. vivax. As there are relatively few locations where P. vivax does not co-exist to some extent with P. falciparum, it is recommended that doxycycline should be used routinely with other agents, for example chloroquine. In acute intestinal amoebiasis Doryx may be a useful adjunct to amoebicides. In severe acne Doryx may be a useful adjunctive therapy.
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on November, 1 2024. To learn more about this subsidy, visit the Pharmaceutical Benefits Scheme (PBS) website.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Reporting side effects
You can help ensure medicines are safe by reporting the side effects you experience.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.
